We work within the growing field of "Physical Oncology". We put a significant amount of effort towards developing treatment paradigms that view the altered physics of tumors as therapeutic opportunities rather than as hindrances to the delivery of more conventional therapies. We are particularly interested in leveraging pulsed electric field therapies to revert the malignant phenotype, either through direct tumor cell killing, or induction of anti-tumor signaling programs. Some example topics are below.



We have developed a pulsed electric field (PEF) ablation method that is capable of preferentially destroying malignant cells based on their altered morphologies, particularly the enlarged nuclear-to-cytoplasmic ratio (NCR) that is often a hallmark of malignant cells. We are now leveraging this approach for treatment of highly infiltrative neoplasms, such as glioblastoma (GBM), in both small and large animal cancers. This work is carried out in close collaboration with the Davalos lab at Virginia Tech.


Based on intriguing in vivo evidence for an anti-tumor immune response following certain classes of pulsed electric field (PEF) therapies, we are studying the fundamental cell signaling responses to non-lethal versions of these treatments. We have recently demonstrated induction of immune profiles in vitro that are known to be tumor suppressive in the tumor microenvironment (TME) in vivo.



Jill W. Ivey, Elisa M. Wasson, Nastaran Alinezhadbalalami, Akanksha Kanitkar, Waldemar Debinski, Zhi Sheng, Rafael V. Davalos, Scott S. Verbridge

Research, 2019, 8081315

Ishan Goswami, Justin B. Perry, Mitchell E. Allen, David A. Brown, Michael R. von Spakovsky, Scott S. Verbridge, 

Biophysical Journal, 2018, v. 114, (12), 2951-2964

Jill W. Ivey, Eduardo L. Latouche, Megan L. Richards, Glenn J. Lesser, Waldemar Debinski, Ravael V. Davalos, Scott S. Verbridge

Biophysical Journal, 2017, v. 113, (2), 472-480


330 Kelly Hall, 325 Stanger St
Blacksburg, Virginia 24061

  • LinkedIn

©2020 by Scott S. Verbridge